Adenocarcinoma: About 40% of lung cancers are adenocarcinomas.
What we found out from today"s news:
These results provide further validation of our targeted approach to treatment using companion imaging and our SMDC technology. We were especially pleased with the results in the adenocarcinoma population and early OS trends, and we have learned important information about the dosing schedule. We look forward to reviewing additional analysis of this study when the OS data has matured later this year to help inform potential further development of the vintafolide/docetaxel combination in NSCLC."
* I'm guessing Merck would have a billion dollar drug (minimum) if limited to adenocarcinomas in US. Should be a nice milestone payment coming as they are likely anxious to design a phase III trial and start enrolling.
GLTA, a good weekend to do the math on the SMDC platform for targeted delivery of not just chemotherapy
I agree with you, and I hope that over the weekend investors realize the potential of what just happened. Endocyte essentially has 1 of 2 medicines to treat PROVAC and has now seen improvement on treating NSCLC which is another difficult cancer to treat. They are building a great platform for a lot of possibilities.